Movement disorder emergencies in the elderly: Recognizing and treating an often-iatrogenic problem

Cleveland Clinic Journal of Medicine

Volumn 75, Issue 6, 2008, Pages 449-457

  Tousi, Babak ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Lutheran Hospital Cleveland   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45849102796     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.6.449     Document Type: Review

References (38)

1. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42:277-285.
2. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96:635-642.
3. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79:201-209.
4. LoCurto MJ. The serotonin syndrome. Emerg Med Clin North Am 1997; 15(3):665-675.
5. Boyer E, Shannon S. The serotonin syndrome. N Engl J Med 2005; 352:1112-1120.
6. Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord 2005; 20:322-334.
7. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73:337-347.
8. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989; 50:295-298.
9. Adityanjee, Singh S, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 1988; 153:107-111.
10. Bonucceill U, Piccini P, Corsini GU, Muratorio A. Apomorphine in malignant syndrome due to levodopa withdrawal. Ital J Neurol Sci 1992; 13:169-170.
11. Sato Y, Asoh T, Metoki N, et al. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 74:574-576.
12. Hariz MI, Johansson F. Hardware failure in parkinsonian patients with chronic subthalamic nucleus stimulation is a medical emergency. Mov Disord 2001; 16:166-168.
13. Pollera CF, Cognetli F, Nardi M, Mozza D. Sudden death after acute dystonic reaction to high-dose metoclopramide. Lancet 1984; 2:460-461.
14. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J 1985; 291:930-932.
15. Pasricha PJ, Pehlivanov N, Sugumar A. Jankovic J. Drug insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006; 3:138-148.
16. Hu S. Frucht S. Emergency treatment of movement disorders. Curr Treat Options Neurol 2007; 9:103-114.
17. Tousi B, Schuele SU, Subramanian T. A 46-year-old woman with rigidity and frequent falls. Cleve Clin J Med 2005; 72:57-63.
18. Merlo IM, Occhini A, Pacchetti C, Alfonsi E. Not paralysis, but dystonia causes stridor in multiple system atrophy. Neurology 2002; 58:649-652.
19. Silber MH, Levine S. Stridor and death in multiple system atrophy. Mov Discord 2000; 15:699-704.
20. Bhatla KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994; 117:859-876.
21. Factor SA, Molho ES. Emergency department presentations of patients with Parkinson's disease. Am J Emerg Med 2000; 18:209-215.
22. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as a treatment for dyskinesia and motor fluctuations in Parkinson's disease. Neurology 1998; 50:1323-1326.
23. Frucht S, Eidelberg D. Imipenem-induced myoclonus. Mov Disord 1997; 12:621-622.
24. Miodownik C, Lerner V, Statsenko N, et al. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol 2006; 29:68-72.
25. Poyurovsky M, Pashinian A, Weizman R. et al. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006; 59:1071-1077.
26. Tousi B, Subramanian T. Hallucinations in Parkinson's disease: approach and management. Clin Geriatr 2004: 12:19-24.
27. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43:2227-2229.
28. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65:115-138.
29. Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 2005; 20:1104-1108.
30. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease. Parkinsonism Relat Disord 2004; 10:253-254.
31. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340:757-763.
32. Merims D, Balas M, Pertez C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29:331-337.
33. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55:789-794.
34. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16:1171-1174.
35. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Discord 2006; 21:1899-1907.
36. Frucht SJ. Movement disorder emergencies in the perioperative period. Neurol Clin 2004, 22:379-387.
37. Korczyn AD, Reichmann H, Boroojerdi B, et al. Rotigotin transdermal system for perioperative administration. J Neural Transm 2007; 114:219-221.
38. Gordon MF. Toxin and drug-induced myoclonus. Adv Neurol 2002; 89:49-76.